A phospholipid-apolipoprotein A-I nanoparticle containing amphotericin B as a drug delivery platform with cell membrane protective properties

International Journal of Pharmaceutics

Volumn 399, Issue 1-2, 2010, Pages 148-155

  Burgess, Braydon L ^a,b   Cavigiolio, Giorgio ^a   Fannucchi, Michelle V ^c   Illek, Beate ^a   Forte, Trudy M ^a,b   Oda, Michael N ^a,b  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b Lypro Biosciences Inc   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Amphotericin B; Apolipoprotein A I; Calu 3 cells; HepG2 cells; High density lipoprotein; Lung epithelium; Membrane protection; Nanodisk; Trans epithelial K+ current

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; APOLIPOPROTEIN A1; DEOXYCHOLIC ACID; LACTATE DEHYDROGENASE; NANODISC; PHOSPHOLIPID; POTASSIUM ION;

APICAL MEMBRANE; ARTICLE; CELL PROTECTION; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EXPOSURE; DRUG FORMULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; ION CURRENT; ION TRANSPORT; LUNG ALVEOLUS CELL; LUNG FUNCTION; LUNG INFECTION; MAMMAL CELL; MEMBRANE PERMEABILITY; NANOPHARMACEUTICS; POTASSIUM CURRENT; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM;

ADMINISTRATION, INHALATION; AMPHOTERICIN B; ANTIFUNGAL AGENTS; APOLIPOPROTEIN A-I; CELL LINE, TUMOR; CELL MEMBRANE; CELL SURVIVAL; DRUG CARRIERS; HUMANS; LUNG; NANOPARTICLES; PHOSPHOLIPIDS; RESPIRATORY MUCOSA;

EID: 77956873194     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.07.057     Document Type: Article

References (28)

1. Behre G.F., Schwartz S., Lenz K., Ludwig W.D., Wandt H., Schilling E., Heinemann V., Link H., Trittin A., Boenisch O., et al. Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Ann. Hematol. 1995, 71:287-291.
2. Bolard J. How do the polyene macrolide antibiotics affect the cellular membrane properties?. Biochim. Biophys. Acta 1986, 864:257-304.
3. Brajtburg J., Bolard J. Carrier effects on biological activity of amphotericin B. Clin. Microbiol. Rev. 1996, 9:512-531.
4. Butler W.T., Cotlove E. Increased permeability of human erythrocytes induced by amphotericin B. J. Infect. Dis. 1971, 123:341-350.
5. Cornet M., Fleury L., Maslo C., Bernard J.F., Brucker G. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J. Hosp. Infect. 2002, 51:288-296.
6. Cowley E.A., Linsdell P. Characterization of basolateral K+ channels underlying anion secretion in the human airway cell line Calu-3. J. Physiol. 2002, 538:747-757.
7. Deuticke B., Kim M., Zollner C. The influence of amphotericin B on the permeability of mammalian erythrocytes to nonelectrolytes, anions and cations. Biochim. Biophys. Acta 1973, 318:345.
8. Gryn J., Goldberg J., Johnson E., Siegel J., Inzerillo J. The toxicity of daily inhaled amphotericin B. Am. J. Clin. Oncol. 1993, 16:43-46.
9. Guo L., Fielding R., Lasic D., Hamilton R., Mufson D. Novel antifungal drug delivery: stable amphotericin B-cholestryl sulfate discs. Int. J. Pharm. 1991, 75:45-54.
10. Hertenstein B., Kern W.V., Schmeiser T., Stefanic M., Bunjes D., Wiesneth M., Novotny J., Heimpel H., Arnold R. Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann. Hematol. 1994, 68:21-26.
11. Holding K.J., Dworkin M.S., Wan P.C., Hanson D.L., Klevens R.M., Jones J.L., Sullivan P.S. Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Adult and Adolescent Spectrum of HIV Disease Project. Clin. Infect. Dis. 2000, 31:1253-1257.
12. Holz R., Finkelstein A. The water and nonelectrolyte permeability induced in thin lipid membranes by the polyene antibiotics nystatin and amphotericin B. J. Gen. Physiol. 1970, 56:125-145.
13. Illek B., Fischer H., Clauss W. Aldosterone regulation of basolateral potassium channels in alveolar epithelium. Am. J. Physiol. 1990, 259:L230-237.
14. Illek B., Fischer H., Kreusel K.M., Hegel U., Clauss W. Volume-sensitive basolateral K+ channels in HT-29/B6 cells: block by lidocaine, quinidine, NPPB, and Ba2+. Am. J. Physiol. 1992, 263:C674-683.
15. Illek B., Fischer H., Clauss W. Quinidine-sensitive K+ channels in the basolateral membrane of embryonic coprodeum epithelium: regulation by aldosterone and thyroxine. J. Comp. Physiol. B 1993, 163:556-562.
16. Janoff A.S., Boni L.T., Popescu M.C., Minchey S.R., Cullis P.R., Madden T.D., Taraschi T., Gruner S.M., Shyamsunder E., Tate M.W., et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:6122-6126.
17. Kuiper L., Ruijgrok E. A review on the clinical use of inhaled amphotericin B. J. Aerosol. Med. Pulm. Drug Deliv. 2009, 22:213-227.
18. Martin D.D., Budamagunta M.S., Ryan R.O., Voss J.C., Oda M.N. Apolipoprotein A-I assumes a " looped belt" conformation on reconstituted high density lipoprotein. J. Biol. Chem. 2006, 281:20418-20426.
19. Menzin J., Meyers J.L., Friedman M., Perfect J.R., Langston A.A., Danna R.P., Papadopoulos G. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am. J. Health Syst. Pharm. 2009, 66:1711-1717.
20. Mohammad R.A., Klein K.C. Inhaled amphotericin B for prophylaxis against invasive Aspergillus infections. Ann. Pharmacother. 2006, 40:2148-2154.
21. Morgan J., Wannemuehler K.A., Marr K.A., Hadley S., Kontoyiannis D.P., Walsh T.J., Fridkin S.K., Pappas P.G., Warnock D.W. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med. Mycol. 2005, 43:S49-58.
22. Nguyen T., Weers P., Raussens V., Wang Z., Ren G., Sulchek T., Hoeprichjr P., Ryan R. Amphotericin B induces interdigitation of apolipoprotein stabilized nanodisk bilayers. Biochim. Biophys. Acta: Biomembr. 2008, 1778:303-312.
23. Oda M.N., Hargreaves P.L., Beckstead J.A., Redmond K.A., van Antwerpen R., Ryan R.O. Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B. J. Lipid Res. 2006, 47:260-267.
24. Palmer S.M., Drew R.H., Whitehouse J.D., Tapson V.F. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001, 72:545-548.
25. Proffitt R.T., Satorius A., Chiang S.M., Sullivan L., Adler-Moore J.P. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J. Antimicrob. Chemother. 1991, 28:49-61.
26. Rijnders B., Cornelissen J., Slobbe L., Becker M., Doorduijn J., Hop W., Ruijgrok E., Löwenberg B., Vulto A., Lugtenburg P., De Marie S. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary Aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin. Infect. Dis. 2008, 46:1401-1408.
27. Yano T., Itoh Y., Kawamura E., Maeda A., Egashira N., Nishida M., Kurose H., Oishi R. Amphotericin B-induced renal tubular cell injury is mediated by Na+ Influx through ion-permeable pores and subsequent activation of mitogen-activated protein kinases and elevation of intracellular Ca2+ concentration. Antimicrob. Agents Chemother. 2009, 53:1420-1426.
28. Zygmunt W.A., Tavormina P.A. Steroid interference with antifungal activity of polyene antibiotics. Appl. Microbiol. 1966, 14:865-869.